Table of Contents

Densification of rituximab plus six cycles of CHOP-14 achieves higher rituximab serum levels, and higher complete response and event-free survival in elderly patients with poor-prognosis DLBCL

NE Oncology Issue - January 2008 Background Age is an important issue in the treatment of diffuse large B-cell lymphoma (DLBCL).1 In the landmark GELA trial, superior progression-free survival (PFS) and overall survival (OS) were reported with R-CHOP-21 in previously...

Rituximab maintenance following high-dose therapy (HDT) and autologous stem cell rescue improves event-free survival and overall survival in patients receiving rituximab as part of pre-HDT cytoreduction

NE Oncology Issue - January 2008 Background Previous studies by Kewalramani and colleagues1 support the addition of rituximab to ICE (ifosfamide, carboplatin, and etoposide) as second-line therapy before autologous stem cell transplantation (ASCT) for patients with...

In vivo purging of B cells with rituximab followed by HDT/ASCT and rituximab maintenance with or without interferon is feasible and well tolerated in high-risk patients with relapsed follicular lymphoma

NE Oncology Issue - January 2008 Meenakshi Kashyap Background High-dose therapy with autologous stem cell transplantation (HDT/ASCT) may prolong remission and survival after first progression in patients with follicular lymphoma.1 In vivo purging of circulating and...

Download Journal

oncol_issue

Contributor

dr-Foley
Ronan Foley, MD
Director of the Stem Cell Laboratory and Chair of the Clinical Trials Network of the Canadian Bone Marrow Transplant Group (CBMTG)
Associate Professor of Pathology and Molecular Medicine, McMaster University

Dr. Foley, a clinical hematologist, completed a Terry Fox Fellowship in the Centre of Gene Therapeutics, McMaster University. During this time, he became interested in the evaluation of cellular gene transfer in the context of cancer immunotherapy, which led to his current research focus: the development of therapeutic cancer vaccines.